{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:13:46Z","timestamp":1790723626732,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009847","name":"CHA University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002559","name":"Sookmyung Women's University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jtha.2024.02.009","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T04:43:02Z","timestamp":1708576982000},"page":"1640-1648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data"],"prefix":"10.1016","volume":"22","author":[{"given":"Hyunjeong","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Young","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Kyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BongKyoo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.02.009_bib1","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.02.009_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12185-018-2545-9","article-title":"Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity","volume":"111","author":"Kitazawa","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2024.02.009_bib3","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.009_bib4","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMc1909742","article-title":"Deaths associated with emicizumab in patients with hemophilia A","volume":"381","author":"Aledort","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.02.009_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/hae.14762","article-title":"Emicizumab prophylaxis in haemophilia A with inhibitors: three years follow-up from the UK Haemophilia Centre Doctors\u2019 Organisation (UKHCDO)","volume":"29","author":"Wall","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.009_bib6","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/jth.14556","article-title":"Emicizumab and thrombosis: the story so far","volume":"17","author":"Makris","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.009_bib7","first-page":"370","article-title":"Thromboembolic risks of non-factor replacement therapies in hemophilia","volume":"37","author":"Tiede","year":"2017","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2024.02.009_bib8","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1182\/blood-2021-146147","article-title":"Evaluation of the safety of emicizumab prophylaxis in persons with hemophilia A: an updated summary of thrombotic events and thrombotic microangiopathies","volume":"138","author":"Howard","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.009_bib9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtha.2023.01.010","article-title":"Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021","volume":"21","author":"Abbattista","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.009_bib10","unstructured":"European Medicines Agency. EudraVigilance support guide. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance; 2016. [accessed July 28, 2023]."},{"key":"10.1016\/j.jtha.2024.02.009_bib11","series-title":"Adverse event reporting system (FAERS)","year":"2018"},{"key":"10.1016\/j.jtha.2024.02.009_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/jth.15186","article-title":"Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database","volume":"19","author":"Pipe","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.009_bib14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s11096-022-01514-4","article-title":"Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database","volume":"45","author":"Wei","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.jtha.2024.02.009_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A\u00a0Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.02.009_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2024.02.009_bib17","series-title":"The UMC measures of disproportionate reporting","year":"2016"},{"key":"10.1016\/j.jtha.2024.02.009_bib18","series-title":"The use of the WHO-UMC system for standardized case causality assessment","year":"2018"},{"key":"10.1016\/j.jtha.2024.02.009_bib19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A\u00a0prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.009_bib20","first-page":"143","article-title":"Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET","volume":"18","author":"Castaman","year":"2020","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jtha.2024.02.009_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hae.13495","article-title":"Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee","volume":"24","author":"Collins","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.009_bib22","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16704","article-title":"Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B","volume":"190","author":"Rayment","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.02.009_bib23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/ejh.13490","article-title":"Emicizumab treatment: impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals)","volume":"105","author":"Nougier","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2024.02.009_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.009_bib25","series-title":"MASAC document 268\u2014recommendation on the use and management of emicizumab-kxwh (Hemlibra) for hemophilia A with and without inhibitors","year":"2022"},{"key":"10.1016\/j.jtha.2024.02.009_bib26","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1111\/hae.14010","article-title":"Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: recommendations from a German expert panel","volume":"27","author":"Escuriola-Ettingshausen","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.009_bib27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2022-169482","article-title":"A\u00a0FVIII-mimetic bispecific antibody with an embedded self-regulation mechanism reduces the risk of prothrombotic events for the treatment of haemophilia A","volume":"140","author":"Muczynski","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.009_bib28","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.ATV.0000168421.13467.82","article-title":"Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition","volume":"25","author":"Dahlb\u00e4ck","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.02.009_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.009_bib30","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1111\/hae.13961","article-title":"Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII","volume":"26","author":"Shimonishi","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.009_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/rth2.12034","article-title":"Clot stability as a determinant of effective factor VIII replacement in hemophilia A","volume":"1","author":"Leong","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.009_bib32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1538-7836.2007.02504.x","article-title":"Structure of fibrin: impact on clot stability","volume":"5","author":"Weisel","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.009_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14524","article-title":"Emicizumab state-of-the-art update","volume":"28","author":"Mahlangu","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.009_bib35","series-title":"A\u00a0guideline on summary of product characteristics","year":"2009"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T23:47:07Z","timestamp":1718840827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624001090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1538783624001090"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.02.009","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}